Related Experiment Video
Updated: May 21, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Polyarteritis nodosa-like vasculitis in association with minocycline use: a single-center case series
Tanaz A Kermani1, Erin K Ham, Michael J Camilleri
1Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. kermani.tanaz@yahoomail.com
Objective:
To describe the clinical features, treatment, and outcomes of polyarteritis nodosa (PAN)-like vasculitis in association with minocycline therapy.
Methods:
We identified all subjects ≥18 years old with PAN-like vasculitis in the context of minocycline use seen at our institution between January 1995 and October 2010. Cases of hepatitis B-associated PAN were excluded. PAN was defined based on angiographic findings or tissue biopsy. Minocycline use was defined as medication use at the time of onset of first symptom.
Results:
We identified 9 patients (5 females; 56%) with a median age of 30 (range 18 to 55) years. Four patients (44%) had isolated cutaneous disease, while 5 cases (56%) had systemic involvement including renal artery microaneurysms (2 patients), cholecystitis (1 patient), mononeuritis multiplex (2 patients), and mesenteric vasculitis (1 patient). Median duration of minocycline use was 2 (range 1 to 4) years. Three patients had a positive antinuclear antibody with negative extractable nuclear antigen antibodies. All patients had positive antineutrophil cytoplasmic antibody in a perinuclear pattern but specificity to myeloperoxidase was observed in 2 patients (22%). Diagnosis was confirmed by histopathology in 6 patients (67%) and angiography in 3 patients (33%). Minocycline was discontinued in all cases. Further immunosuppressive therapy was added in 6 cases (67%).
Conclusions:
Cutaneous, as well as systemic, PAN-like vasculitis may occur in association with minocycline use. Clinicians should consider the possibility of drug-induced vasculitis, especially in cases of medium-vessel vasculitis with atypical antineutrophil cytoplasmic antibody serologies or in patients with negative hepatitis B testing.
Insights
Minocycline can cause polyarteritis nodosa (PAN)-like vasculitis, affecting skin or organs. Discontinuation of minocycline and immunosuppressants are key treatments for this drug-induced vasculitis.
Area of Science:
- Rheumatology
- Dermatology
- Internal Medicine
Background:
- Polyarteritis nodosa (PAN) is a rare systemic vasculitis.
- Minocycline is an antibiotic used for various infections and inflammatory conditions.
- Drug-induced vasculitis is an important differential diagnosis in patients presenting with vasculitic symptoms.
Purpose of the Study:
- To investigate the clinical presentation, treatment strategies, and outcomes of patients developing PAN-like vasculitis.
- To determine the association between minocycline therapy and the onset of PAN-like vasculitis.
- To raise awareness among clinicians regarding this potential adverse effect of minocycline.
Main Methods:
- Retrospective review of patients diagnosed with PAN-like vasculitis and minocycline use.
- Inclusion criteria: age ≥18 years, minocycline use at symptom onset, exclusion of hepatitis B-associated PAN.
- Diagnostic confirmation through angiography or tissue biopsy.
Main Results:
- Nine patients (56% female, median age 30) were identified.
- 56% presented with systemic involvement (e.g., renal artery microaneurysms, mesenteric vasculitis).
- Diagnosis confirmed by histopathology (67%) or angiography (33%); minocycline was discontinued in all cases.
Conclusions:
- Minocycline therapy can be associated with the development of PAN-like vasculitis, both cutaneous and systemic.
- Clinicians should consider minocycline as a potential cause of medium-vessel vasculitis.
- Atypical ANCA serologies or negative hepatitis B testing in the context of vasculitis should prompt consideration of drug-induced causes.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Nephrotic Syndrome I : Introduction
Myocarditis III: Medical Management
Endocarditis III: Medical Management
